Microbiome Manufacturing Market Revenue to Cross US$ 187 million by 2035

Published: February 2024


According to a recently published report by Roots Analysis, the growing pipeline of microbiome-based therapies and preference for outsourcing manufacturing related operations are driving the microbiome manufacturing market growth

Microbiome Manufacturing Industry Overview

The global microbiome manufacturing market is anticipated to grow at a CAGR of 17% from 2023-2035, reaching USD 187 million by 2035

With the approval of therapeutics like Vowst and Rebyota, and continuous advancement of other promising microbiome-based therapeutics to clinical stages, the microbiome manufacturing market has witnessed notable growth. The therapeutic potential of the human microbiota is being evaluated across various disease indications, including digestive disorders, dermatological disorders and oncological disorders with a focus on maintaining an intricate balance of microorganisms in the human body for various health benefits. From fecal microbiota transplantation to personalized probiotics, researchers are exploring novel ways to manipulate the microbiome to treat various rare disorders. Ongoing studies aim to uncover the specific mechanisms underlining these therapies, paving the way for a more targeted and effective approach to harness the potential of the microbiomes for medical purposes. Given the extensive research efforts, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years.

Browse 155+ figures and 160+ market data tables spread across 280+ pages and detailed Table of Content on “Microbiome Manufacturing Market by Type of Product Manufactured, Type of Formulation, Type of Primary Packaging Used, Scale of Operation, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/microbiome-contract-manufacturing/306.html

Market Drivers

Several factors contribute to the growth of the microbiome manufacturing market. The growing incidence of chronic diseases has increased demand for effective and targeted treatments, such as microbiome therapies, creating lucrative opportunities for microbiome manufacturers. In addition, a number of microbiome?based medicines, which may already be approved for use in humans by the FDA in the form of commonly consumed foods, contribute to the increase in pipeline, further propelling growth in manufacturing market. Further, the reliance of microbiome therapy developers on the CMOs and CDMOs has been on a rise for outsourcing various operations. These CMOs and CDMOs are increasingly focusing on enhancing their offerings by incorporating novel technologies in order to streamline the manufacturing process.

Market Restraints

One of the primary restraints of the microbiome industry is the need for robust technologies and a meticulously controlled manufacturing process. Such products are usually temperature sensitive; this makes the overall manufacturing process more challenging since a temperature-controlled environment needs to be maintained throughout. Additionally, for large scale manufacturing of microbiome therapies, the requirement of introducing living microbes into a host environment while ensuring the desired effect without harm, acts as a limiting factor, as setting up of cGMP facilities and obtaining the necessary qualifications and certifications is difficult. Moreover, the stringent regulatory requirements to ensure quality, consistency and purity of microbiome therapies can also hinder the growth.

Growth Factors

Despite several challenges, various growth factors continue to drive the microbiome manufacturing market. One of the notable factors is the use of genomics to identify individual therapeutic microorganisms and design customized therapies. Further, advances in biotechnology and immunology have paved the way for innovative approaches in harnessing these therapies. Additionally, a considerable increase in research and development efforts, coupled with increasing investments from both public and private sectors, has accelerated the manufacturing of these therapies. Moreover, collaborations among pharmaceutical companies, academic institutions, and research organizations to address unmet medical needs globally are likely drive considerable growth in the market.

Microbiome Manufacturing Market Segments

Based on the type of product manufactured, the market is segmented into APIs and FDFs.

  • The API segment led the microbiome manufacturing market, capturing the largest revenue share of close to 56% in 2023.
  • In fact, the API segment is anticipated to witness the highest market growth rate of over 18%, annually during the forecast period.

Based on the type of formulation, the market is segmented into Solid, Liquid and Others.

  • The liquid formulation segment led the microbiome manufacturing market, capturing the largest revenue share of close to 48% in 2023.
  • The solid formulation segment is anticipated to witness the highest market growth rate of around 17%, annually during the forecast period.

Based on the type of primary packaging used, the market is segmented into Pouches / Sachets, Glass / Plastic Bottles, Blister Packs and Vials.

  • Pouches / Sachets segment led the microbiome manufacturing market, capturing the largest revenue share of more than 30% in 2023.
  • Blister Packs segment is anticipated to witness the highest market growth rate of over 18%, annually during the forecast period.

Based on the scale of operation, the market is segmented into Clinical and Commercial.

  • The commercial scale of operation has led the microbiome manufacturing market, capturing the largest revenue share of close to 81% in 2023.
  • In fact, both clinical and commercial scale is anticipated to witness a market growth rate of over 17%, annually during the forecast period.

Based on the company size, the market is segmented into Small, Mid-sized, Large and Very Large

  • The small company size segment led the microbiome manufacturing market, capturing the largest revenue share of close to 42% in 2023.
  • Further, the small company size segment is anticipated to witness the highest market growth rate of over 19%, annually during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World

  • Europe dominated the microbiome manufacturing market and accounted for the largest revenue share of over 53% in 2023.
  • In Europe, the microbiome manufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

Microbiome Manufacturing Market Key Companies Profiled

The microbiome manufacturing market report also includes detailed profiles of key players (listed below) that offer microbiome manufacturing services:

  • Capsugel
  • Fujifilm Diosynth Biotechnologies
  • List Biological Laboratories
  • ProbioFerm
  • Arranta Bio
  • Biose Industrie
  • Cerbios-Pharma
  • Chr. Hansen
  • Inpac Probiotics
  • NIZO
  • WACKER
  • Winclove Probiotics
  • BacThera
  • Evologic Technologies
  • Probiotical
  • Quay Pharma
  • BJP Laboratories
  • AcuraBio
  • Unique Biotech
  • Aumgene Biosciences
  • Probiotics Australia
  • Meteoric Biopharmaceuticals

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/microbiome-contract-manufacturing/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry